Navigation Links
8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, Study Finds
Date:10/5/2009

LOS ANGELES, Oct. 5 /PRNewswire/ -- According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk. At 18 months, there was no reduction in the progression of CIMT in the group as a whole. However, further analysis revealed an indication that the rate of CIMT progression slowed in nearly one third of patients, those with elevated cardiovascular disease risk factors. This study was funded by POM Wonderful.

Conducted at Radiant Research in Chicago, IL, and University of Texas Southwestern Medical Center in Dallas, TX, this randomized, placebo-controlled, double-blind trial involved 289 subjects at varying degrees of moderate heart disease risk who consumed 8 ounces per day of either POM Wonderful 100% Pomegranate Juice or a placebo beverage. The trial's endpoint was the increase in CIMT, a measurement which includes both the artery wall itself as well as accumulated plaque. CIMT measurements were recorded at both 12 and 18 months after the treatment began.

The composite measurement of CIMT showed a significantly smaller value at 12 months in the pomegranate juice group compared to the control group (0.79 vs 0.81 mm, p = 0.022), although this difference was no longer significant at the end of the treatment period (0.79 vs 0.80 mm, p = 0.168). The results from post hoc exploratory analyses, which should be interpreted with caution, suggest that rate of CIMT progression may have been slowed in high-risk subgroups. Specifically, the authors found statistically lower CIMT values within several subgroups of patients with elevated cardiovascular risk factors, including high total triglycerides as well as low HDL cholesterol as compared to total cholesterol and triglycerides.

"This study was initiated based on the compelling results from pre-clinical studies and an initial clinical trial," said lead researcher Michael H. Davidson, MD. "We are excited with the outcome of this larger study because while we did not see a reduction in the group as a whole, there is an indication that the rate of CIMT progression slowed in subgroups of patients characterized by more rapid CIMT progression."

In conclusion, the authors call for these preliminary findings to be investigated in future studies, because "consumption of pomegranate juice is very safe; thus demonstration of a benefit on atherosclerotic disease progression, even in a subset of the population, would have important public health implications."

The publication of this study is the most recent in series of studies evaluating the potential benefits of POM Wonderful 100% Pomegranate Juice on human health. In 1998 POM Wonderful initiated a world class medical research program to investigate the Wonderful variety pomegranate. To date, POM Wonderful has funded $32 million in research, which has involved a number of top scientists from leading universities around the world, including a Nobel Laureate. So far, 48 total studies have been published in peer-review journals. Primary research areas have included the prostate and cardiovascular, among others.

Source Cited:

M. Davidson et al., Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease, American Journal of Cardiology (2009)

About POM Wonderful

POM Wonderful is the largest producer of California Wonderful pomegranates and the company exclusively grows and sells this variety. POM Wonderful's pomegranates grow in central California, in the sunny San Joaquin Valley. Fresh pomegranates are in season from October through January and November is National Pomegranate Month.

POM Wonderful also uses its fresh pomegranates to make its delicious, all-natural POM Wonderful 100% Pomegranate Juice and extract POMx, an all-natural, ultra-potent concentration of polyphenol antioxidants. POMx is available exclusively in POMx Iced Coffee, POMx Tea, POMx Pills, POMx Bars and POMx Shots. POM Wonderful Pomegranate Juice and POMx Tea are available year-round in the refrigerated section of produce departments in supermarkets nationwide. POMx Iced Coffee, POMx Pills, POMx Bars and POMx Shots are available in select US markets. POMx Pills are also available at www.pompills.com. To learn more, visit www.pomwonderful.com.

SOURCE POM Wonderful


'/>"/>
SOURCE POM Wonderful
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: